Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9

Cancer Science

Volumn 99, Issue 3, 2008, Pages 553-563

  Moro, Loredana ^a   Arbini, Arnaldo A ^b,c   Yao, Jorge L ^c   di Sant'Agnese, Paul A ^c   Marra, Ersilia ^a   Greco, Margherita ^a  

^a CNR   (Italy)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BRCA2 PROTEIN; COLLAGEN; FIBRONECTIN; GELATINASE B; LAMININ; MATRIGEL; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN DEGRADATION; PROTEIN DEPLETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPINDLE CELL; UPREGULATION; WILD TYPE;

EID: 38949084511     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00719.x     Document Type: Article

References (44)

1. Furuta E, Bandyopadhyay S, Iiizumi M, Mohinta S, Zhan R, Watabe K. The role of tumor metastasis suppressors in cancers of breast and prostate. Front Biosci 2006; 11: 2845-60.
2. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
3. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-9.
4. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424-32.
5. Thant AA, Nawa A, Kikkawa F et al. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 2000; 18: 423-8.
6. Bonaccorsi L, Marchiani S, Muratori M, Carloni V, Forti G, Baldi E. Signaling mechanisms that mediate invasion in prostate cancer cells. Ann NY Acad Sci 2004; 1028: 283-8.
7. Li L, Ittmann MM, Ayala G et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005; 8: 108-18.
8. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-82.
9. Edwards SM, Kote-Jarai Z, Meitz J et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12.
10. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol 2004; 22: 735-42.
11. Gudmundsson J, Johannesdottir G, Bergthorsson JT et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995; 55: 4830-2.
12. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-72.
13. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004; 95: 866-71.
14. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006; 34: 633-45.
15. Wang SC, Shao R, Pao AY, Zhang S, Hung MC, Su LK. Inhibition of cancer cell growth by BRCA2. Cancer Res 2002; 62: 1311-14.
16. Moro L, Arbini AA, Marra E, Greco M. Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation. J Biol Chem 2005; 280: 22482-91.
17. Tian XX, Rai D, Li J et al. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res 2005; 65: 4747-53.
18. Moro L, Arbini AA, Marra E, Greco M. Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem 2006; 281: 22100-7.
19. Moro L, Arbini AA, Marra E, Greco M. Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. Int J Oncol 2007; 30: 217-24.
20. Huang J, Yao JL, Zhang L et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166: 1807-15.
21. Ni J, Wen X, Yao J et al. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res 2005; 65: 9807-16.
22. Moro L, Perlino E, Marra E, Languino LR, Greco M. Regulation of beta1C and beta1A integrin expression in prostate carcinoma cells. J Biol Chem 2004; 279: 1692-702.
23. Buccione R, Orth JD, McNiven MA. Foot and mouth. podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol 2004; 5: 647-57.
24. Leung TH, Ching YP, Yam JW et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 2005; 102: 15207-12.
25. Zi X, Guo Y, Simoneau AR et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005; 65: 9762-70.
26. Gupta GP, Massague J. Cancer metastasis: Building a framework. Cell 2006; 127: 679-95.
27. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006; 66: 4816-25.
28. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003; 10: 823-32.
29. Collier IE, Bruns GA, Goldberg GI, Gerhard DS. On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. Genomics 1991; 9: 429-34.
30. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
31. Ruhul Amin AR, Senga T, Oo ML, Thant AA, Hamaguchi M. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta. A role for the dual signalling pathways, Akt and Erk. Genes Cells 2003; 8: 515-23.
32. Jorda M, Olmeda D, Vinyals A et al. Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the snail transcription factor. J Cell Sci 2005; 118: 3371-85.
33. Iyer V, Pumiglia K, DiPersio CM. Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: A novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005; 118: 1185-95.
34. Yuen MT, Leung LK, Wang J, Wong YC, Chan FL. Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int J Oncol 2005; 27: 1685-95.
35. Hampl JA, Hampl M, Reiss G, Koch R, Saeger HD, Schackert HK. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients. Anticancer Res 2004; 24: 281-90.
36. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res 2003; 63: 8511-5.
37. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004; 7: 327-32.
38. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol 2002; 41: 289-96.
39. Cardillo MR, Di Silverio F, Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 2006; 26: 973-82.
40. Nair RR, Solway J, Boyd DD. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem 2006; 281: 26424-36.
41. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 1999; 10: 407-16.
42. Jiang Y, Muschel RJ. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res 2002; 62: 1910-4.
43. Kreisberg JI, Malik SN, Prihoda TJ et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-6.
44. Malik SN, Brattain M, Ghosh PM et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-71.